BMJ:发送电子邮件提醒可显著提高ClinicalTrials.gov的结果提交率

2014-11-03 佚名 医伟达

2014年9月发表在 BMJ 的一项试验,向未履行相关法律要求的试验负责人发送电子邮件,提醒他们提交结果的法律要求。结果发现,尽管3个月时在ClinicalTrials.gov上的结果提交率尚未改善,但是6个月时得以显著提高。(在线课堂:文献检索—如何利用Clinicaltrials检索临床研究资料)目的:给未履行食品和药品管理法修正案801法律要求的完成试验的负责人发送电子邮件以提醒提交研究结果

2014年9月发表在 BMJ 的一项试验,向未履行相关法律要求的试验负责人发送电子邮件,提醒他们提交结果的法律要求。结果发现,尽管3个月时在ClinicalTrials.gov上的结果提交率尚未改善,但是6个月时得以显著提高。(在线课堂:文献检索—如何利用Clinicaltrials检索临床研究资料

目的:给未履行食品和药品管理法修正案801法律要求的完成试验的负责人发送电子邮件以提醒提交研究结果,评估该干预措施的效果。[pdf free]

设计:队列嵌入式随机对照试验

设置:已在ClinicalTrials.gov上注册的试验

参与者:由电脑随机选取的379项试验中的190项试验随机接受干预措施(以调查问卷形式构建了个性化的电子邮件,并发送给试验的负责人,间接提醒他们相关的法律要求和未履行该法律要求的潜在不良后果)。

主要结局测量:主要结局为3个月时向ClinicalTrials.gov提交结果的比例。次要结局为6个月时提交结果的比例。然后两名评估者提取被ClinicalTrials.gov接收最初结果的日期。研究人员进行了排除错误纳入的研究的事后敏感度分析。

结果:在纳入的379项试验中,190项随机接受了电子邮件干预。电子邮件干预组和未干预组之间,在3个月时提交结果的比例并无差异:36/190(19%)vs 24/189(13%)(相对风险,1.5,95% CI,0.9~2.4,P=0.096),但是,6个月时具有差异:46/190(24%)vs 27/189(14%)(1.7,1.1~2.6,P=0.014)。在敏感度分析中(分别排除了48/379项试验(13%)、26/190(14%)、22/189(12%))),该结果在3个月(相对风险5.1,1.1~22.9,P=0.02)和6个月(4.1,1.3~10.6,P=0.001)时的差异具有统计学意义。

结论:发送关于在ClinicalTrials.gov上提交结果的FDA法律要求的电子邮件提醒,可显著改善6个月时的提交率,但是3个月时没有改善。

原始出处:



热门推荐:



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056941, encodeId=279f2056941a6, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Nov 09 08:16:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860978, encodeId=ec0d18609e8fe, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 22 07:16:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952286, encodeId=3a3519522860e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Sat Oct 17 01:16:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847623, encodeId=85ee184e62397, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Feb 25 20:16:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507609, encodeId=9122150e609f7, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631318, encodeId=155c163131890, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=)]
    2014-11-09 zhzhxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056941, encodeId=279f2056941a6, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Nov 09 08:16:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860978, encodeId=ec0d18609e8fe, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 22 07:16:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952286, encodeId=3a3519522860e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Sat Oct 17 01:16:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847623, encodeId=85ee184e62397, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Feb 25 20:16:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507609, encodeId=9122150e609f7, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631318, encodeId=155c163131890, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=)]
    2015-09-22 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056941, encodeId=279f2056941a6, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Nov 09 08:16:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860978, encodeId=ec0d18609e8fe, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 22 07:16:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952286, encodeId=3a3519522860e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Sat Oct 17 01:16:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847623, encodeId=85ee184e62397, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Feb 25 20:16:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507609, encodeId=9122150e609f7, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631318, encodeId=155c163131890, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056941, encodeId=279f2056941a6, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Nov 09 08:16:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860978, encodeId=ec0d18609e8fe, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 22 07:16:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952286, encodeId=3a3519522860e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Sat Oct 17 01:16:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847623, encodeId=85ee184e62397, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Feb 25 20:16:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507609, encodeId=9122150e609f7, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631318, encodeId=155c163131890, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=)]
    2015-02-25 gaoxiaoe
  5. [GetPortalCommentsPageByObjectIdResponse(id=2056941, encodeId=279f2056941a6, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Nov 09 08:16:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860978, encodeId=ec0d18609e8fe, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 22 07:16:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952286, encodeId=3a3519522860e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Sat Oct 17 01:16:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847623, encodeId=85ee184e62397, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Feb 25 20:16:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507609, encodeId=9122150e609f7, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631318, encodeId=155c163131890, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=)]
    2014-11-05 zll0628
  6. [GetPortalCommentsPageByObjectIdResponse(id=2056941, encodeId=279f2056941a6, content=<a href='/topic/show?id=bcb11e80913' target=_blank style='color:#2F92EE;'>#trials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17809, encryptionId=bcb11e80913, topicName=trials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Nov 09 08:16:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860978, encodeId=ec0d18609e8fe, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 22 07:16:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952286, encodeId=3a3519522860e, content=<a href='/topic/show?id=225e484e42' target=_blank style='color:#2F92EE;'>#ClinicalTrials.gov#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4847, encryptionId=225e484e42, topicName=ClinicalTrials.gov)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e524260, createdName=dinorsor524, createdTime=Sat Oct 17 01:16:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847623, encodeId=85ee184e62397, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Feb 25 20:16:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507609, encodeId=9122150e609f7, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631318, encodeId=155c163131890, content=<a href='/topic/show?id=ae581e80805' target=_blank style='color:#2F92EE;'>#Trial#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17808, encryptionId=ae581e80805, topicName=Trial)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1ad21715548, createdName=feifers, createdTime=Wed Nov 05 06:16:00 CST 2014, time=2014-11-05, status=1, ipAttribution=)]
    2014-11-05 feifers

相关资讯

ClinicalTrials.gov网站临床试验注册指导

    临床试验注册一直是医学文献、通俗媒体以及美国议会所关注的焦点问题。临床试验的注册库都属于网络数据库,收录临床试验的资料,兼有伦理和学术双重作用。这些注册库确保公众对目前正在开展或既往已开展项目的了解,从而发挥伦理作用;同时还可为研究人员、期刊编辑人员和审稿专家提供一些解读研究结果所需的背景资料;通过完整罗列各项临床试验的目录清单,还可提示研究人员对当前尚未